Apex Labs

Actual: Jan 3, 2023

Health Canada No Objection Letter granted for PATHFINDER-52 Phase 2b trial (n=294, take-home microdose psilocybin for PTSD).

Why it matters: HC NOL enables enrollment of the largest psilocybin microdose trial globally. The take-home design breaks the in-clinic paradigm that limits scalability of psychedelic therapy.

Actual: Mar 29, 2023

STEP-52 proof-of-concept study completed March 29, 2023. Met all primary and secondary endpoints over a two-month period. Zero adverse events. Confirmed safety, efficacy, and tolerability of take-home APEX-52 in PTSD-diagnosed Veterans. Also evaluated symptom stability when transitioning from unregulated psilocybin to GMP APEX-52.

Why it matters: First controlled data for a take-home oral microdose psilocybin formulation. Zero AE profile and endpoint success enabled PATHFINDER-52 Phase 2b initiation. The transition-stability data addresses a practical concern for Veterans already self-medicating with unregulated psilocybin.

Actual: Feb 14, 2024

Health Canada Controlled Drugs and Substances Dealer's Licence granted, authorizing sale of APEX-52 and APEX-90 psilocybin products.

Why it matters: Dealer's Licence is a prerequisite for commercial-scale supply and distribution. Positions Apex for both clinical supply and future SAP/EAP expansion.

Actual: Mar 7, 2024

US patent application filed for proprietary capsule drug delivery system — improved bioavailability, oxidative stability, and thermal stability for psilocybin formulation.

Why it matters: Patent protection for the capsule formulation strengthens Apex's IP moat beyond the clinical data package.

Actual: Jun 20, 2024

FDA IND filed for APEX-52 (take-home oral microdose psilocybin) for Yale PK/driving simulator study (n=55). Study will determine PK of psilocybin (time to undetectable blood levels) and driving performance at Cmax.

Why it matters: US IND filing opens a second regulatory jurisdiction. The Yale driving study answers a critical real-world safety question for home-dosing psilocybin — if patients can safely drive post-dose, it removes a major barrier to take-home prescribing. Note: FDA clearance has not been publicly confirmed 22 months post-filing.

Watch next: FDA IND clearance confirmation; Yale PK/driving data

Actual: Apr 14, 2023

Health Canada No Objection Letter granted for SUMMIT-90 Phase 2b trial (n=160, macrodose psilocybin with psychotherapy for severe PTSD).

Why it matters: Enables the multi-dose macrodose arm of Apex's twin-track strategy (microdose take-home + macrodose in-clinic). SUMMIT-90 addresses the most severe end of the PTSD spectrum where macrodose sessions may be required.

Actual: Nov 15, 2023

First Canadian Veteran dosed with APEX-90 macrodose psilocybin under Apex's Early Access Program (EAP) via Health Canada Special Access Program (SAP).

Why it matters: Real-world clinical use in a Veteran under SAP generates safety data and patient experience data ahead of full Phase 2b enrollment. Demonstrates the regulatory pathway for compassionate access.

Actual: Jun 12, 2025

Israeli Ministry of Health approved SUMMIT-90 expansion to two Israeli sites: Tel Aviv University's Institute for Psychedelic Research at the Sagol Brain Institute, and Be'er Yaakov Mental Hospital's Center for Psychedelic Studies.

Why it matters: Israel adds military PTSD expertise from the IDF research community and accelerates enrollment. Israel's acute mental health crisis (44% adults report depression, 42% PTSD) creates a motivated patient population.